Tenax Therapeutics
Price & Volume
Stats
See more52W Range | $2.77-$21.45 |
Market Cap | $21.2M |
Shares Short | 204,516 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$13.05 |
News
See moreYahoo Finance • last year
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
Yahoo Finance • last year
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
Yahoo Finance • 2 years ago
Tenax Therapeutics Provides 2023 Business Update
Yahoo Finance • 2 years ago
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
About
CEO | Mr. Christopher T. Giordano |
Address | 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 5 |
